`Date Filed: July 12, 2016
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`ARGENTUM PHARMACEUTICALS LIMITED,
`Petitioner
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`Patent Owner
`
`________________
`
`Case IPR2016-01317
`Patent 8,822,438
`
`________________
`
`
`JANSSEN ONCOLOGY, INC.’S MANDATORY NOTICES
`
`
`
`
`
`
`
`
`
`
`IPR2016-01317
`Patent 8,822,438
`
`Janssen Oncology, Inc. submits the following mandatory notices pursuant to
`
`37 C.F.R. §42.8
`
`REAL PARTY-IN-INTEREST
`
`Janssen Oncology, Inc., a wholly-owned subsidiary of Johnson & Johnson
`
`(“J&J”), is a real party-in-interest. J&J, a publicly held company, is also a real
`
`party-in-interest. In addition, BTG International Limited, a subsidiary of BTG plc,
`
`is a real party-in-interest.
`
`RELATED MATTERS
`
`U.S. Patent 8,822,438 (the “’438 Patent”) issued from U.S. Application No.
`
`13/034,340 (the “’340 Application”). U.S. Patent Application No. 15/019,353,
`
`which is currently pending before the Office, claims the benefit of the ’340
`
`Application.
`
`The ’438 Patent was the subject of ex parte reexamination request No.
`
`90/020,096 (the “’096 reexamination”). On June 14, 2016, the Office issued a
`
`Notice of Termination of Preprocessing of the ’096 reexamination. As a result, the
`
`’096 reexamination will not be granted a filing date for failure to comply with the
`
`requirements of 37 C.F.R. § 1.501(a). See Ex. 2001.
`
`The ’438 Patent is the subject of inter partes reviews IPR2016-00286, which
`
`was instituted on May 31, 2016 and was filed by Amerigen Pharmaceuticals
`
`2
`
`
`
`IPR2016-01317
`Patent 8,822,438
`
`Limited, and IPR2016-01332, which was filed by Mylan Pharmaceuticals Inc. on
`
`June 30, 2016.
`
`The ’438 Patent is being asserted in the following patent infringement
`
`lawsuits:
`
` BTG International Limited, et al. v. Actavis Laboratories FL, Inc., et
`
`al., C.A. No. 2:15-cv-05909-KM-JBC (D.N.J.) (the “District of New
`
`Jersey Action”);
`
` Janssen Biotech, Inc., et al. v. Mylan Pharmaceuticals Inc., et al.,
`
`C.A. No. 1:15-cv-00130-IMK (N.D. W. Va.) (stayed; conditional trial
`
`date set for February 2018);
`
` BTG International Limited, et al. v. Amerigen Pharmaceuticals, Inc.,
`
`et al., C.A. No. 2:16-cv-02449-KM-JBC (D.N.J.); and
`
` BTG International Limited, et al. v. Glenmark Pharmaceuticals Inc.,
`
`USA et al., C.A. No. 2:16-cv-05909 (D.N.J.).
`
`The ’438 Patent was asserted in the following patent infringement lawsuits
`
`that have now been terminated:
`
` Janssen Biotech, Inc., et al. v. Par Pharmaceutical, Inc., et al., C.A.
`
`No. 1:15-cv-00679-SLR (D. Del.); and
`
` BTG International Limited, et al. v. Actavis Laboratories FL, Inc., et
`
`al., C.A. No. 9:15-cv-81076-DMM (S.D. Fla.).
`
`3
`
`
`
`IPR2016-01317
`Patent 8,822,438
`
`
`LEAD AND BACKUP COUNSEL
`
`Lead Counsel
`
`Dianne B. Elderkin (Reg. No. 28,598)
`delderkin@akingump.com
`AKIN GUMP STRAUSS HAUER
`& FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`Tel.: (215) 965-1340
`Fax: (215) 965-1210
`
`
`Backup Counsel
`
`
`Barbara L. Mullin (Reg. No. 38,250)
`bmullin@akingump.com
`Ruben H. Munoz (Reg. No. 66,998)
`rmunoz@akingump.com
`AKIN GUMP STRAUSS HAUER
`& FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`Tel.: (215) 965-1200
`Fax: (215) 965-1210
`
`
`
`4
`
`
`
`
`
`
`
`
`
`IPR2016-01317
`Patent 8,822,438
`
`SERVICE INFORMATION
`
`Janssen consents to electronic service at the following email address:
`
`JANS-ZYTIGA@akingump.com
`ZytigaIPRTeam@sidley.com
`
`
`
`Janssen may be served courtesy copies by postal mailing or hand-delivery as
`
`follows:
`
`
`
`Dianne B. Elderkin
`AKIN GUMP STRAUSS HAUER & FELD LLP
`Two Commerce Square
`2001 Market Street, Suite 4100
`Philadelphia, PA 19103
`Tel.: (215) 965-1340
`Fax: (215) 965-1210
`
`
`
`Respectfully submitted,
`
`
`
`/s/Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`
`
`
`
`
`
`
`
`Date: July 12, 2016
`
`
`
`5
`
`
`
`IPR2016-01317
`Patent 8,822,438
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Janssen
`
`Oncology, Inc. Mandatory Notices as well as Exhibit 2001 were served on counsel
`
`of record on July 12, 2016 by filing this document through the Patent Review
`
`Processing System, as well as delivering a copy via electronic mail to counsel of
`
`record for the Petitioner at the following addresses:
`
`Teresa Stanek Rea – TRea@Crowell.com
`Shannon M. Lentz – SLentz@Crowell.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /s/Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`
`
`Date: July 12, 2016
`
`
`
`
`
`
`
`
`
`
`
`6